Download or read book Tumor Markers in Cancer Control and Therapy written by and published by . This book was released on 1988 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Human tumor markers written by and published by . This book was released on 1987 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Tumor Markers in Cancer Control and Therapy written by Janis V. Klavins and published by . This book was released on 1987 with total page 137 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Tumor Markers in Cancer Control written by Johann Heinrich Holzner and published by . This book was released on 1985 with total page 366 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Tumor Markers in Cancer Control written by Herbert E. Nieburgs and published by . This book was released on 1985-12 with total page 362 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Diet and Cancer written by Maryce M. Jacobs and published by Springer Science & Business Media. This book was released on 2013-11-22 with total page 267 pages. Available in PDF, EPUB and Kindle. Book excerpt: The American Institute for Cancer Research (AICR) sponsored its third annual confer ence on nutrition and cancer. The theme was "Diet and Cancer: Markers, Prevention, and Treatment. " The conference was held October 29-30, 1992 at the Ritz Carlton Hotel in McLean, Virginia. This proceedings contains chapters from the platform presentations and abstracts from the poster presentations. Several chapters address each of four session topics: Retinoids as Differentiation Agents in Cancer Therapy, Biological Markers of Cancer Risk, Chemoprevention of Cancer by Non-Nutrients in Foods, and Nutritional Problems and Support in the Treatment of Cancer. The first three chapters discuss in detail different mechanisms by which retinoids influence differentiation and provide evidence to support their use in cancer therapy. In vivo and in vitro studies show the effects of retinoic acid (RA) on tumorigenicity and cellu lar/molecular events. A synopsis of data showing the involvement of the retinoblastoma (RB) gene in HL-60 cell differentiation induced by RA and 1,2S-dihydroxy vitamin D3 (VD) is presented. In SCID (severe combined immunodeficiency) mice injected with HL-60 3 human leukemia cells and gavaged daily with RA, the number of tumor sites and number of mice with tumors are reduced. All trans-RA induces myeloid differentiation in HL-60 cells. Similarly, VD3 induces HL-60 monocytic differentiation. In both cases an early down regulation of retinoblastoma (RB) gene expression precedes the differentiation.

Download or read book Biomarkers in Cancer Screening and Early Detection written by Sudhir Srivastava and published by John Wiley & Sons. This book was released on 2017-08-28 with total page 334 pages. Available in PDF, EPUB and Kindle. Book excerpt: Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers Provides immediately actionable information – and hopefully also inspiration – to move discovery and clinical application forward Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers

Download or read book Cancer written by Gary S. Stein and published by John Wiley & Sons. This book was released on 2019-07-09 with total page 680 pages. Available in PDF, EPUB and Kindle. Book excerpt: A guide to recent insights into the genetic and epigenetic parameters of cancer biology and pathology and emerging clinical applications The thoroughly updated second edition of The Biology and Treatment of Cancer, now titled Cancer: Prevention, Early Detection, Treatment and Recovery, goes beyond reviewing the fundamental properties of cancer biology and the relevant issues associated with treatment of the disease. The new edition contains coverage of additional "patient centric" topics and presents cancer biology with selection of topics, facts, and perspectives written in easy-to-understand terms. With contributions from noted experts, the book explores recent advances in the understanding of cancer including breakthroughs in the molecular and cellular basis of cancer and provides strategies for approaching cancer prevention, early detection, and treatment. The authors incorporate recent information on the genetic and epigenetic parameters of cancer biology and pathology with indications of emerging clinical applications. The text offers a unique guide to cancer prevention, early detection, treatment, and recovery for students, caregivers, and most importantly cancer patients. This significant book: Incorporates current insight into the genetic and epigenetic parameters of cancer biology and pathology and information on emerging clinical applications Contains contributions from leaders in cancer research, care, and clinical trials Offers an accessible guide to an accurate and balanced understanding of cancer and the cancer patient Focuses on the importance of cancer prevention, early detection, treatment, and survivorship Written for medical students, students of cancer biology, and caregivers and cancer patients, Cancer: Prevention, Early Detection, Treatment and Recovery offers an authoritative overview of the challenges and opportunities associated with cancer biology, cancer research, and the spectrum of clinical considerations.

Download or read book Molecular Biomarkers for Cancer Diagnosis and Therapy written by Ranbir Chander Sobti and published by Springer. This book was released on 2023-08-30 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents recent advancements, challenges, and clinical implications of molecular biomarkers in various cancers. This book highlights the clinical applications of biomarkers are extensive for cancer risk assessment, screening and early detection of cancer, accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring response. It also explores the progress of predictive biomarkers as an adjunctive tool to tumor immunotherapy in effectively identifying the efficacy of immune checkpoint inhibitors and discusses their future directions in achieving precision immuno-oncology. Further, the book examines the combination of next-generation sequencing and advanced computational data analysis approaches in the understanding of the genomic underpinnings of cancer development and progression. Towards the end, the chapter discusses the role of some commonly investigated phytochemicals and their epigenetic targets that are of particular interest in cancer prevention and cancer therapy. It is a must for researchers as well as advanced students and physicians in the field of cancer and clinical oncologists.

Download or read book Developing Biomarker Based Tools for Cancer Screening Diagnosis and Treatment written by Institute of Medicine and published by National Academies Press. This book was released on 2006-10-18 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt: Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice. To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.

Download or read book Researches on New Generation Tumor Markers written by Yildiz Dincer, Ph.d. and published by . This book was released on 2019-02-22 with total page 339 pages. Available in PDF, EPUB and Kindle. Book excerpt: Many cancers are associated with the abnormal production of some molecules which can be measured in plasma/urine or can be detected on the surface of resected tumor tissue. These molecules are known as tumor markers. The potential uses of tumor markers are screening in the general population, differential diagnoses of symptomatic patients, clinical staging of cancer, estimating tumor volume, indicating prognosis, monitoring treatment and detecting recurrences. In order to obtain maximum clinical benefit, a tumor marker should have some characteristics. A tumor marker should be tissue-specific. The plasma level of the tumor marker should be in proportion to the size and activity of the tumor. A tumor marker should be present in plasma at a detectable level, even though tumor size is very small. A tumor marker should reflect the altered tumor characteristic as a response to therapy. Unfortunately, currently used tumor markers do not meet all of these criteria. A majority of them are present in normal, benign and tumor tissues, and unfortunately, they are not specific enough to be used for cancer screening in the general population. In addition, conventional tumor markers are poor in reflecting altered tumor behavior in response to anticancer therapy. They are of most value during follow-up appointments. Recent developments in molecular biology have led to the identification of numerous new tumor biomarkers. Firstly, the detection of DNA and RNA freely circulating in blood has provided a new perspective for the early diagnosis of cancer, patient follow-up, and assessment of therapy efficacy. Circulating free nucleic acids can originate from both malignant and non-malignant tissues. Discrimination of tumor cells is based on the presence of tumor-specific genetic and epigenetic alterations. This circulating nucleic acid-based approach is termed a liquid biopsy. Due to its non-invasive and repeatable features, liquid biopsy is a promising tool for cancer patients. It is particularly helpful in cancers where solid tissue biopsies are not feasible, and in the metastatic patients when multiple distinct tumor masses are simultaneously present. As another advantage, liquid biopsy shows the current tumor dynamics during anticancer therapy and drug sensitivities that conventional examinations fail to reflect. Secondly, self-renewable stem cells have the potential to cause cancer. If stem cells are genetically or epienetically changed, their differentiation potential becomes impaired and their proliferative capacity becomes uncontrolled. Current anticancer therapies mostly fail to eradicate cancer stem cells and instead favor expansion of the cancer stem cell pool and/or select for resistant stem cells. Thirdly, microRNAs, non-coding RNAs and transfer RNA fragments found in the bloodstream are candidate markers for the diagnosis and prognosis of different types of cancer. This book provides an overview of these new molecular tumor markers.

Download or read book European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis written by Nereo Segnan and published by . This book was released on 2010 with total page 452 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recoge: 1. Introduction -- 2. Organisation -- Guiding principles for organising a colorectal cancer screening programme -- 3. Evaluation and interpretation of screening outcomes -- 4. Faecal occult blood testing -- 5. Quality assurance in endoscopy in colorectal cancer screening and diagnosis -- 6. Professional requirements and training -- 7. Quality assurance in pathology in colorectal cancer screening and diagnosis -- 8. Management of lesions detected in colorectal cancer screening -- 9. Colonoscopic surveillance following adenoma removal --10. Communication -- Appendices.

Download or read book Prognostic Factors in Cancer written by Paul Hermanek and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 303 pages. Available in PDF, EPUB and Kindle. Book excerpt: M. K. Gospodarowicz, P. Hermanek, and D. E. Henson Attention to innovations in cancer treatment has tended to eclipse the importance of prognostic assessment. However, the recognition that prognostic factors often have a greater impact on outcome than available therapies and the proliferation of biochemical, molecular, and genetic markers have resulted in renewed interest in this field. The outcome in patients with cancer is determined by a combination of numerous factors. Presently, the most widely recognized are the extent of disease, histologic type of tumor, and treatment. It has been known for some time that additional factors also influence outcome. These include histologic grade, lymphatic or vascular invasion, mitotic index, performance status, symptoms, and most recently genetic and biochemical markers. It is the aim of this volume to compile those prognostic factors that have emerged as important determinants of outcome for tumors at various sites. This compilation represents the first phase of a more extensive process to integrate all prognostic factors in cancer to further enhance the prediction of outcome following treatment. Certain issues surround ing the assessment and reporting of prognostic factors are also considered. Importance of Prognostic Factors Prognostic factors in cancer often have an immense influence on outcome, while treatment often has a much weaker effect. For example, the influence of the presence of lymph node involvement on survival of patients with metastatic breast cancer is much greater than the effect of adjuvant treatment with tamoxifen in the same group of patients [5].

Download or read book Tumor Markers written by Eleftherios P. Diamandis and published by Amer. Assoc. for Clinical Chemistry. This book was released on 2002 with total page 580 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Tumor Marker Protocols written by Margaret Hanausek and published by Humana Press. This book was released on 2010-10-28 with total page 500 pages. Available in PDF, EPUB and Kindle. Book excerpt: The development of cancer is a slow process and it very often takes a number of years before a tumor becomes clinically evident. No current te- nique is sensitive and specific enough to detect tumors at their earliest stage, i. e. , when the tumor is smaller than one billion cells. Consequently, the d- ease is usually diagnosed in an advanced state, very often when it is already beyond the reach of therapeutic strategies. This is the main stumbling block to the secondary prevention that would reduce cancer mortality. There is hope, however, because in the last decade we have witnessed an explosion of reports dealing with tumor markers. In many instances, simple, noninvasive diagnostic tests are becoming available to detect the early signs ofneoplasia. Interest in early detection of neoplasia is growing among those basic scientists, cli- cians, and health professionals who realize that progress in reducing cancer mortality is dependent to a great degree on its early detection and prevention. Some disappointment usually accompanies these discoveries, because what at first glance proves to be promising, is in many instances, applicable only to a limited number of cases. What is the cause of these failures? The answer may be that cancer is a multitude of neoplastic diseases in which endogenous and exogenous etiologic factors contribute either sim- taneously or over a lifetime to the development of disease.

Download or read book Tumor Markers written by Nasser Javadpour and published by Praeger. This book was released on 1987-02-17 with total page 312 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor markers, or antigens, are subtances produced in the body by malignant tumors. Their detection is useful in both diagnosing cancer and monitoring therapy. This straight-forward book provides a comprehensive overview designed to assist physicians who deal with cancer patients. The contributions by leading authorities include discussions of techniques for detecting tumor markers, steroid receptors, monoclonal antibodies, flow cytometry, chromosomal abnormalities, radioimmunodetection, ectopic hormones, cell markers in leukemia, nucleolar antigens, and non-specific markers.

Download or read book Biomarkers in Breast Cancer written by Giampietro Gasparini and published by Springer Science & Business Media. This book was released on 2008-01-17 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.